Effectiveness and cost-effectiveness of Crestor 5 mg are verified, AstraZeneca Korea says

Published: 2013-08-21 07:00:00

Updated: 2013-08-21 07:00:00

In the previous clinical trial of 1,851 Korean patients with dyslipidemia, Crestor 5 mg (rosuvastatin) is more effective and cost-effective in lowering low-density lipoprotein cholesterol (LDL-C) and in attainment of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP I...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK